Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended December 31, 2007 (Fiscal Year 2008)
Business Overview: Cardinal Health is a leading provider of healthcare products and services, operating primarily through four segments: Healthcare Supply Chain Services (Pharmaceutical and Medical), Clinical Technologies and Services, and Medical Products and Technologies. The company distributes pharmaceuticals and medical supplies to hospitals, clinics, and retail outlets.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Dec 31, 2007 |
3 Months Ended Dec 31, 2006 |
6 Months Ended Dec 31, 2007 |
6 Months Ended Dec 31, 2006 |
|---|---|---|---|---|
| Revenue | $23,282.7 | $21,784.6 | $45,256.1 | $42,722.1 |
| Gross Margin | $1,354.6 | $1,299.9 | $2,696.8 | $2,500.4 |
| Operating Earnings | $519.2 | $511.9 | $1,009.0 | $963.0 |
| Net Earnings | $324.7 | $739.3 | $626.5 | $1,010.0 |
| Diluted EPS | $0.89 | $1.80 | $1.70 | $2.45 |
| Cash from Operating Activities | N/A | N/A | $382.6 | $639.8 |
| Cash and Equivalents (Balance Sheet) | $1,184.4 | N/A | $1,184.4 | N/A |
Note: Net earnings for the prior year periods included significant income from discontinued operations ($423.8M for the quarter and $403.1M for the six months), which were largely absent in the current period.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 7% ($1.5B) for the quarter and 6% ($2.5B) for the six months, driven by pharmaceutical price appreciation (6.7% index), volume growth, and acquisitions (notably Viasys).
- Profitability: Operating earnings increased 1% for the quarter and 5% for the six months. However, Net Earnings decreased significantly (56% for the quarter, 38% for six months) primarily due to the absence of discontinued operations income from the prior year.
- Segment Performance:
- Pharmaceutical: Revenue grew 6%, but segment profit declined 21% due to increased customer discounts, contract repricing, and generic deflation.
- Medical Products & Technologies: Revenue surged 47% and profit increased 46%, largely driven by the Viasys acquisition.
- Clinical Technologies: Profit increased 26% (quarter) and 49% (six months) due to favorable product mix and revenue growth.
- Special Items: Total special items were $29.5M (quarter) and $52.0M (six months), including $31.5M in restructuring charges and $10.0M in acquisition integration costs. These were partially offset by $23.0M in litigation settlement income.
- Cash Flow: Operating cash flow decreased $257M year-over-year for the six-month period due to increased working capital requirements (higher inventory and lower accounts payable).
Guidance, Outlook, Risks, and Unusual Items
- DEA Investigation: The Drug Enforcement Administration (DEA) suspended licenses for three distribution centers (Auburn, Lakeland, Swedesboro) in late 2007 due to concerns over controlled substance diversion. The company expects significant expenses and lost revenue in fiscal 2008 related to this matter.
- Product Recall: A Class 1 recall was issued for Alaris Pump modules (approx. 200,000 units) due to potential over-infusion risks. The company accrued $14.0M for recall costs for the six months ended Dec 31, 2007.
- Legal Settlements: The company settled federal securities litigation for $600M (reserved in prior year) and ERISA litigation for $40M. It also recognized $23M income from derivative litigation settlements.
- Share Repurchases: The company repurchased approximately $350M of common shares in the quarter and $600M for the six months under active authorization programs.
- Outlook: Management expects competitive pricing pressures to continue but anticipates mitigation through higher-margin manufactured products and cost controls. The DEA matter is expected to adversely affect results in fiscal 2008.
Key Facts for Investor Verification
- Discontinued Operations Impact: Verify the comparability of net earnings by excluding the $423.8M gain from discontinued operations in the prior year quarter.
- DEA License Status: Monitor the resolution of the DEA license suspensions and the associated financial impact on the Pharmaceutical segment.
- Working Capital Trends: Assess the sustainability of the $254M increase in inventory and $180M decrease in accounts payable driving the decline in operating cash flow.
- Restructuring Costs: Track the remaining estimated costs of $102.9M associated with ongoing restructuring and integration activities.
- Customer Concentration: Review the impact of bulk customer sales (which have lower margins) versus non-bulk sales on overall profitability.